Solid Tumors: Assessment of CAR-T Cell Killing Capacity - Webinar

Webinar October, 20 4:00 pm GMT summer time.

CAR T therapies targeting solid tumors

Chimeric Antigen Receptor (CAR) T cells have shown substantial promise in treating liquid cancers such as B cell leukemia. The complexity of solid tumors, however, has caused the development of effective CAR T cell therapies against these tumors to lag behind. Robust CAR design and sensitive yet realistic functional testing will be required in order to improve the efficacy of CAR T cell therapies targeting solid tumors.

Killing Capacity of CAR T Components

We have used the xCELLigence® Real-Time Cell Analyzer as a high-throughput platform to test multiple CAR components including ex­tracellular domains (including bi-specifics), signaling endo-domains, as well as next-generation CAR T cell products that are inherently resistant to checkpoint blockade. This platform has proven very sensitive to subtle yet longitudinally meaningful differences in CAR design, and has made it possible to evaluate T cell products in a "stress test" that is more representative of early phase trial requirements.

Register here

 

Speaker:

Nabil Ahmed, Associate Professor of Pediatrics, Baylor College of Medicine

Dr. Nabil Ahmed received his M.D. and M.P.H degrees from the Faculty of Medicine at Cairo University. He subsequently conducted residencies at Lincoln Hospital of Weill-Cornell Medical College and the Children’s Hospital of New Jersey of Mount Sinai School of Medicine.

Dr. Ahmed is currently an Associate Professor of Pediatrics at Baylor College of Medicine. He is a physician scientist and board cer­tified pediatric oncologist who is engaged in translational research focused on understanding how the immune system interacts with solid tumors. In particular, he is studying adoptive immunotherapy using gene-modified effector cells to target solid tumors. His initial studies demonstrated that antigen-specific cytotoxic T cells can eradicate established tumors in glioma, osteosarcoma, and medul­loblastoma models. Subsequent studies have demonstrated that tumor-specific T cells can effectively target the stem cells present in these tumors. Aligning with this primary research interest, he also studies the role of T cells in creating a tumor niche, and T cell migration to distant tumor sites in the brain.

Dr. Ahmed has experience in developing and translating cell therapy studies to the clinic. He currently serves as the Principal Investigator for 3 clinical trials targeting osteosarcoma and glioblastoma. All studies are FDA, IRB, RAC and IBC approved.

 

 
 

Passende Artikel

xCELLigence SP

Platzsparendes Single-Plate System im 96-well Format xCelligence SP: Single Plate System; 96 well E-Plates im Standard-Format mit geringem Raumbedarf im Inkubator für die Echtzeit Zellanalytik. Dynamische, markerfreie Echtzeit Zell-Analytik mit hoher Datenqualität, weitem Anwendungsbereich, vollständig automatischer Daten-Aufzeichnung und vielseitiger intuitiver Analysesoftware. Die überlegene Technologie zur...

Preis auf Anfrage

2801000

xCELLigence MP

Das hochflexible System für hohen Datendurchsatz oder Multi-User Einsatz xCELLigence MP: Multi-Plate System - für 6 x 96 well E-Plates. Hochflexibel: für den hohen Datendurchsatz oder parallele Experimente mehrerer Anwender. Dynamische markerfreie Echtzeit Zell-Analytik mit hoher Datenqualität, weitem Anwendungsbereich, vollständig automatischer Daten-Aufzeichnung und vielseitiger intuitiver Analysesoftware. Die...

Preis auf Anfrage

2801003

 
 

Kommentar schreiben

 

Die mit einem * markierten Felder sind Pflichtfelder.